We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Fondaparinux Requires Further Study Before Firm Recommendation

Steven J. Hughes, FRCS(orth)
Arch Intern Med. 2003;163(4):498. doi:10.1001/archinte.163.4.498a.
Text Size: A A A
Published online


British orthopedic surgeons are a skeptical group, and when it comes to chemoprophylaxis for venous thromboembolism, strong opinions are guaranteed to emerge, especially in the light of a new anticoagulant. The editorial by Heit1 clearly highlights the clinical and economic arguments for thromboprophylaxis and succinctly outlines the potential benefits and shortcomings of fondaparinux compared with low-molecular-weight heparin.1 Fondaparinux offers a benefit with an overall 50% reduction in venographic deep vein thrombosis, but without reduction in symptomatic end points at day 11 or in fatal and nonfatal pulmonary embolism and mortality at day 49.2 Even if the venographic reductions translated into fractional reductions in clinical end points, such a marginal reduction must be balanced against an absolute 1% increase in bleeding.1,3 Safety is the central concern of surgeons in the United Kingdom, not marginal increases in efficacy. One of the fondaparinux studies investigated hip fracture and highlighted the need for improved thromboprophylaxis strategy in these patients (fatal thromboembolic events occurred in 1% at day 49).4 As with most clinical trials, the patients with hip fracture were highly selected; those with impaired renal function or any hemorrhagic tendency were excluded. Although the need for improved prophylaxis is clear, elderly, fragile patients with hip fracture must be carefully screened before exposure to fondaparinux, especially given its long half-life and lack of antidote. Given the price premium for fondaparinux (more than 50% in the United Kingdom), I concur with Heit1 that detailed cost-effectiveness analyses, both from a US and a UK perspective, are required before this novel synthetic indirect factor Xa inhibitor can be firmly recommended.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles